Development of Acute Tolerance to Bumetanide: Constant-Rate Infusion Studies
dc.contributor.author | Smith, David E. | en_US |
dc.contributor.author | Cook, Jack A. | en_US |
dc.date.accessioned | 2006-09-08T19:20:48Z | |
dc.date.available | 2006-09-08T19:20:48Z | |
dc.date.issued | 1988-02 | en_US |
dc.identifier.citation | Cook, Jack A.; Smith, David E.; (1988). "Development of Acute Tolerance to Bumetanide: Constant-Rate Infusion Studies." Pharmaceutical Research 5(2): 86-91. <http://hdl.handle.net/2027.42/41519> | en_US |
dc.identifier.issn | 1573-904X | en_US |
dc.identifier.issn | 0724-8741 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/41519 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3247297&dopt=citation | en_US |
dc.description.abstract | Bumetanide was administered intravenously to four mongrel dogs as a bolus of 8.7 µg/kg, immediately followed by a constant-rate infusion of 0.35 µg/min/kg at 0.036 ml/min. Treatment A consisted of a 90-min equilibration period and first hour (Phase I) of study in which animals were maintained under euvolemic conditions. During the subsequent 3 hr of Treatment A (Phase II), animals were maintained under hydropenic conditions. These experiments were then repeated 1 week later (Treatment B) with the temporal aspects of hydration reversed (Phase III, hydropenia; Phase IV, euvolemia). Serial plasma and urine samples were assayed for bumetanide by high-performance liquid chromatography (HPLC) and for sodium by flame photometry. The bumetanide excretion rate was not significantly different during the 4 hr of Treatment A, although minor differences were observed between Phase III and Phase IV of Treatment B. The sodium excretion rate showed significant differences between euvolemic and hydropenic conditions of both treatments. A two- to threefold difference in the sodium excretion rate persisted even when slight differences (<20%) in bumetanide excretion rates were taken into account. These results demonstrate that an acute tolerance does develop to constant-rate infusions of bumetanide when inadequate fluid and electrolyte replacement occurs and that this tolerance can be reversed by rehydration. | en_US |
dc.format.extent | 863920 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Dynamics | en_US |
dc.subject.other | Bumetanide | en_US |
dc.subject.other | Medical Law | en_US |
dc.subject.other | Kinetics | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Acute Tolerance | en_US |
dc.title | Development of Acute Tolerance to Bumetanide: Constant-Rate Infusion Studies | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, Ann Arbor, Michigan, 48109-1065 | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, Ann Arbor, Michigan, 48109-1065 | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 3247297 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/41519/1/11095_2004_Article_306146.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1015984016680 | en_US |
dc.identifier.source | Pharmaceutical Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.